Transient down-modulation of CD20 by rituximab in patients with chronic lymphocytic leukemia

Iman Jilani, Susan O'Brien, Taghi Manshuri, Deborah A. Thomas, Vilmos A. Thomazy, Maha Imam, Sana Naeem, Srdan Verstovsek, Hagop Kantarjian, Francis Giles, Michael Keating, Maher Albitar*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

101 Scopus citations

Abstract

Lymphoid cells in most patients with chronic lymphocytic leukemia (CLL), when treated with rituximab, become CD20-. This is thought to be due to masking of CD20 by rituximab. We used specific antimouse immunoglobulin antibodies to detect rituximab on the surface of CLL lymphocytes and we demonstrate that rituximab is rarely detectable after therapy. Only 3 of 65 patients with CLL had rituximab detectable on their lymphocytes after rituximab therapy despite the fact that most had no detectable CD20 expression. In vitro mixing of CLL or Raji cells with rituximab demonstrated that rituximab was detectable on the surface of cells due to its binding to CD20. However, the addition of plasma led to the down-modulation of CD20 expression, and the rituximab became undetectable. This down-modulation of CD20 protein expression was associated with a down-modulation of CD20 mRNA. CLL cells that lost their CD20 expression regained CD20 expression after 24 hours in culture. These data suggest that rituximab therapy leads to a substantial but transient down-modulation of CD20 expression and that negativity for CD20 in cells from patients treated with rituximab is not necessarily due to CD20 masking. The importance of this down-modulation in the efficacy of current therapy with rituximab needs further investigation.

Original languageEnglish (US)
Pages (from-to)3514-3520
Number of pages7
JournalBlood
Volume102
Issue number10
DOIs
StatePublished - Nov 15 2003

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Fingerprint

Dive into the research topics of 'Transient down-modulation of CD20 by rituximab in patients with chronic lymphocytic leukemia'. Together they form a unique fingerprint.

Cite this